Literature DB >> 25248573

Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification.

Hosub Park1, Soyeon An1, Soo-Heang Eo2, Ki-Byung Song3, Jin-hong Park4, Kyu-pyo Kim5, Sang Soo Lee6, HyungJun Cho2, Dong-Wan Seo6, Song Cheol Kim3, Eunsil Yu1, Seung-Mo Hong7.   

Abstract

The T classification for pancreatic cancer of the American Joint Committee on Cancer may be inaccurate owing to lack of consideration of tumor size in cases of extension beyond the pancreas. To examine the accuracy of American Joint Committee on Cancer staging and to determine the prognostic implication of combined tumor size and extrapancreatic extension, 6145 cases of pancreatic ductal adenocarcinomas from the Surveillance, Epidemiology, and End Results database were categorized according to tumor size and extension as follows: group 1 (G1, ≤2 cm and limited to the pancreas), G2 (>2 cm and limited to the pancreas), G3 (≤2 cm with extrapancreatic extension), and G4 (>2 cm with extrapancreatic extension). The median survival of G1, G2, G3, and G4 were 23, 15, 19, and 14 months, respectively (P < .001), and the survival time in G3 was closer to that of G2 than G4. To test the classification system for accuracy of prognosis, G3 was merged with G2. The survival discrimination of this new grouping was greater (overall comparison, P < .001; G1 versus G2 + G3, P < .001; G2 + G3 versus G4, P < .001; χ(2) = 92.043) than that of the current T-classification scheme (overall comparison, P < .001; G1 versus G2, P < .001; G2 versus G3 + G4, P = .048; χ(2) = 60.424). To better discriminate survival, patients with a tumor less than or equal to 2 cm extending beyond the pancreas should be downstaged from the current class T3 to class T2.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pancreatic cancer; Pancreatic ductal adenocarcinoma; Prognosis; T classification; Tumor burden

Mesh:

Year:  2014        PMID: 25248573     DOI: 10.1016/j.humpath.2014.06.030

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Extended lymphadenectomy benefits patients with borderline resectable pancreatic head cancer-a single-center retrospective study.

Authors:  Jing Wang; Shao-Cheng Lyu; Ji-Qiao Zhu; Xian-Liang Li; Ren Lang; Qiang He
Journal:  Gland Surg       Date:  2021-10

2.  Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.

Authors:  Burcu Saka; Serdar Balci; Olca Basturk; Pelin Bagci; Lauren M Postlewait; Shishir Maithel; Jessica Knight; Bassel El-Rayes; David Kooby; Juan Sarmiento; Takashi Muraki; Irma Oliva; Sudeshna Bandyopadhyay; Gizem Akkas; Michael Goodman; Michelle D Reid; Alyssa Krasinskas; Rhonda Everett; Volkan Adsay
Journal:  Ann Surg Oncol       Date:  2016-01-29       Impact factor: 5.344

3.  Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.

Authors:  Deyali Chatterjee; Matthew H Katz; Wai Chin Foo; Manonmani Sundar; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Anirban Maitra; Jason B Fleming; Asif Rashid; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2017-08       Impact factor: 6.298

4.  Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis.

Authors:  Yiquan Jiang; Yanhong Su; Yutong Chen; Zhiyong Li
Journal:  J Cancer       Date:  2017-08-23       Impact factor: 4.207

5.  Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report.

Authors:  Mariacristina Di Marco; Riccardo Carloni; Stefania De Lorenzo; Cristina Mosconi; Andrea Palloni; Elisa Grassi; Daria Maria Filippini; Angela Dalia Ricci; Alessandro Rizzo; Alessandro Di Federico; Donatella Santini; Daniela Turchetti; Claudio Ricci; Carlo Ingaldi; Laura Alberici; Francesco Minni; Rita Golfieri; Giovanni Brandi; Riccardo Casadei
Journal:  World J Gastrointest Oncol       Date:  2020-12-15

6.  Correlation of tumor size and survival in pancreatic cancer.

Authors:  Caitlin Takahashi; Ravi Shridhar; Jamie Huston; Kenneth Meredith
Journal:  J Gastrointest Oncol       Date:  2018-10

7.  Thymoma size significantly affects the survival, metastasis and effectiveness of adjuvant therapies: a population based study.

Authors:  Dongliang Bian; Feng Zhou; Weiguang Yang; Kaixuan Zhang; Linsong Chen; Gening Jiang; Peng Zhang; Chunyan Wu; Ke Fei; Lei Zhang
Journal:  Oncotarget       Date:  2018-01-23

8.  Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis.

Authors:  Xiaogang Li; Shanmiao Gou; Zhiqiang Liu; Zeng Ye; Chunyou Wang
Journal:  Cancer Med       Date:  2018-01-29       Impact factor: 4.452

Review 9.  Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomy specimens.

Authors:  Eline Soer; Lodewijk Brosens; Marc van de Vijver; Frederike Dijk; Marie-Louise van Velthuysen; Arantza Farina-Sarasqueta; Hans Morreau; Johan Offerhaus; Lianne Koens; Joanne Verheij
Journal:  Virchows Arch       Date:  2018-03-27       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.